

DMD #63750

Investigation of Host-Gut Microbiota Modulation of Therapeutic Outcome

Lian Yee Yip and Eric Chun Yong Chan

Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science
Drive 4, Singapore 117543, Singapore (L.Y.Y. and E.C.Y.C.)

Bioprocessing Technology Institute, Agency for Science Technology and Research
(A*STAR), 20 Biopolis Way, #06-01 Centros, Singapore 138668, Singapore (L.Y.Y.)

DMD #63750

Title

Investigation of Host-Gut Microbiota Modulation of Therapeutic Outcome

Corresponding author:

Dr Eric Chun Yong Chan
Associate Professor
Department of Pharmacy
National University of Singapore
18 Science Drive 4
Singapore 117543
Tel: (65) 65166137
Fax: (65) 67791554
E-mail: phaccye@nus.edu.sg

Manuscript information

No. of text pages: 22
No. of tables: 2
No. of figures: 2
No. of references: 181
No. of words: Abstract (156 words)
Content (6500 words)

Nonstandard abbreviations

COMET – Consortium for Metabonomic Toxicology
CYP – Cytochrome P450
DGGE – Denaturing gradient gel electrophoresis
FISH – Fluorescence *in situ* hybridization
GC/TOFMS – Gas chromatography time-of-flight mass spectrometry
GMD – Golm Metabolome Database
HMDB – Human Metabolome Database
LC/MS – Liquid chromatography-mass spectrometry
MS – Mass spectrometry
NIST – National Institute of Standards and Technology
NMR – Nuclear magnetic resonance
qPCR – quantitative polymerase chain reaction
rRNA – ribosomal ribonucleic acid
SPF – Specific pathogen-free
TGGE – Temperature gradient gel electrophoresis
T-RFLP – Terminal restriction fragment length polymorphism

DMD #63750

Abstract

A broader understanding towards factors underlying inter-individual variation in pharmacotherapy is important for our pursuit of “personalized medicine”. Based on knowledge gleaned from the investigation of the human genetics, drug metabolizing enzymes and transporters, clinicians and pharmacists are able to tailor pharmacotherapies according to the genotype of patients. However, human host factors only form part of the equation that accounts for heterogeneity in therapeutic outcome. Notably, the gut microbiota possesses wide ranging metabolic activities that expands the metabolic functions of the human host beyond that encoded by the human genome. This review will first illustrate with examples the mechanisms in which gut microbes modulate pharmacokinetics and therapeutic outcome. Secondly, we discuss the application of metabonomics in deciphering the complex host-gut microbiota interaction in pharmacotherapy. Thirdly, we highlight an integrative approach with particular mention of the investigation of gut microbiota using culture-based and culture-independent techniques to complement the investigation of the host-gut microbiota axes in pharmaceutical research.

DMD #63750

Introduction

Our unique age, gender, genetic makeup, nutritional state, disease condition and environmental exposure influence therapeutic outcomes. The recognition of inter-individual differences in drug response has thus spawned the move towards “Personalized Medicine” (Mancinelli et al., 2000; Ginsburg and McCarthy, 2001; Woodcock, 2007; Hamburg and Collins, 2010). The ability to truly provide personalized medical care is dependent on mechanistic knowledge underlying heterogeneity in drug responses. With the emergence of ‘omics’ technologies, there has been a paradigm shift towards investigating diseases and drug therapies using the omics-based systems biology approach (Zhou et al., 2008; Lum et al., 2009; Bates, 2010; Chan and Ginsburg, 2011). The recommendation by the United States Food and Drug Administration (USFDA) to genotype patients prior to treatment with trastuzumab, clopidogrel, carbamazepine and irinotecan due to their differential efficacy and toxicity in stratified patient cohorts demonstrated the value of pharmacogenomics in predicting drug responses (Khoury et al., 2009; Leckband et al., 2013). Nonetheless, host genetics alone does not explain all variations in pharmacotherapy (Nebert et al., 2003).

In fact, human beings have been coined as “superorganisms” since our complex systems biology is dictated by two sets of genomes – the genetically inherited human genome and the environmentally acquired microbiome (Lederberg, 2000). It has been estimated that there are approximately 10^{12} parenchymal cells in human (excluding blood cells and neurons) and 10^{12} bacteria on the skin, 10^{10} in the mouth, and 10^{14} in the guts (Kumar et al., 2013). Considering the 10-fold higher proportion of microbial to human cells, the extragenomic influence by the microbiome on systems biology should not be underestimated (Savage, 1977; Holmes et al., 2012; Nicholson et al., 2012). Indeed, accumulating evidence revealed the diverse impacts of the microbiome on human health, including nutrition, physiology and host metabolism

DMD #63750

(Nicholson et al., 2012; Guinane and Cotter, 2013). Dysbiosis of microbiome has also been linked to pathological conditions such as inflammatory bowel diseases (Morgan et al., 2012; Kostic et al., 2014), diabetes (Qin et al., 2012), obesity (Turnbaugh et al., 2006; Turnbaugh et al., 2009; Sweeney and Morton, 2013) and autism (Kang et al., 2013).

From an anatomical perspective, the gut microbiota forms an important external “organ” within the gastrointestinal ecosystem, comprising more than 400 different species of bacteria (Hao and Lee, 2004; Qin et al., 2010). Notably, these intestinal bacteria contributes about 1.5 kg of the human body weight (Toivanen et al., 2001), comparable to the weight of major human organs such as the liver (~1.5 kg) and brain (~1.4 kg) and exceeds that of the lung (~0.84 kg), kidney (~0.27 kg) and spleen (~0.14 kg) (Molina and DiMaio, 2012). Importantly, the gut microbiota performs functional activities not encoded by the host genome. For example, desert woodrats living in the Mojave desert of USA were found to harbor gut microbiota that facilitates their dietary consumption of highly toxic creosote bush that invaded their habitat 17,000 years ago (Karasov, 1989). The leaves of the creosote bush are covered with a phenolic-rich resin that is largely made up of nordihydroguaiaretic acid that is known to induce kidney cysts and liver damage in laboratory rodents (Lambert et al., 2002; Arteaga et al., 2005). Kohl *et al.* demonstrated that the distinct gut microbiota communities residing in Mojave woodrats confer tolerance to the creosote plant toxins by having higher abundance of microbes with genes that facilitate metabolism and detoxification of the aromatic toxic compounds compared to the naïve woodrats lacking similar ecological and evolutionary experience with creosote (Kohl et al., 2014). This example highlighted how microbial adaptation expands the host’s enzymatic repertoire and confers the host with competitive advantage through access to nutrients that are otherwise toxic to other competitors incapable of performing microbial detoxification (Dearing et al., 2005).

DMD #63750

Similarly, the metabolic crosstalk between the host and gut microbiota modulates the pharmacokinetics and pharmacodynamics of drugs (Sousa et al., 2008; Holmes et al., 2012; Haiser and Turnbaugh, 2013; Li and Jia, 2013; Carmody and Turnbaugh, 2014). In this review, we first offer an overview of how pharmacokinetics and therapeutic outcomes are affected by a number of key established host-gut microbiota interactions. Secondly, we discuss the application of metabolomics in deciphering the complex host-gut microbiota interaction underlying inter-individual variation in therapeutic outcome. Thirdly, we propose an integrative approach to investigate the gut microbiota with a special focus on culture-based and culture-independent techniques.

Host-Gut Microbiota Modulation of Pharmacokinetics and Therapeutic Outcome

The Liver in Pharmacokinetic and Therapeutic Outcome

To understand pharmacokinetic and therapeutic outcome, pharmaceutical scientists have placed much attention in investigating the host (e.g. species, gene expression, genetic polymorphism, disease, gender and age), drug (e.g. chemical structure, dosage and frequency of administration) and other xeno-compounds (e.g. diet, supplements and other concomitant drugs) rather than the gut microbiota (Wilson and Nicholson, 2009). The liver being a major organ responsible for metabolizing xenobiotics has received special attention. The liver plays a central role in biotransformation of drugs and is equipped with a range of metabolizing enzymes and transporters necessary for its function. In Phase I functionalization reactions (e.g. oxidation, reduction and hydrolysis), polar functional groups are introduced to nonpolar molecules. Cytochrome P450 (CYP) is a major class of drug metabolizing enzymes in the liver responsible for Phase I metabolism (Wrighton and Stevens, 1992; Spatzenegger and Jaeger, 1995; Iyanagi, 2007). Phase II enzymes (e.g. UDP-glucuronosyltransferase, sulfotransferases or glutathione-S-transferases) catalyze conjugation reactions that add polar

DMD #63750

moieties such as glucuronic acid, sulfate or glutathione to the functional groups (Iyanagi, 2007). These processes facilitate the clearance of the xenobiotics via the urinary or biliary route with the aid of transporters or efflux pumps. Considering the key roles of the hepatic metabolizing enzymes and transporters in pharmacokinetics, factors such as induction, inhibition and genetic polymorphism that lead to alterations in the expression and functional activities of these enzymes and transporters, may contribute to inter-individual variation in pharmacokinetics and therapeutic outcome (Park and Breckenridge, 1981; Park et al., 1996; Ingelman-Sundberg et al., 1999; Ando et al., 2000; Shenfield, 2004; Bosch et al., 2006; Guengerich, 2006; Ieiri et al., 2006; Kerb, 2006; Tomalik-Scharte et al., 2007). However, these factors do not account for all forms of heterogeneity among individuals.

Gut Microbiota Modulates Pharmacokinetics and Therapeutic Outcome

In recent years, the interest to elucidate the roles of the gut microbiota on pharmacokinetics and therapeutic outcomes has rekindled. The gut microbiota is known to possess a diverse range of metabolic activities that are capable of modulating the fate of an administered drug and its therapeutic outcome (Scheline, 1968; Nicholson et al., 2005; Sousa et al., 2008; Clayton et al., 2009; Haiser and Turnbaugh, 2012; Haiser et al., 2013). Scheline has even proposed that the gut microbiota has the metabolic potential at least equivalent to the liver (Scheline, 1973).

Mechanistically, the gut microbiota is known to affect pharmacokinetics by partaking in the direct metabolism of xenobiotics or through its indirect interaction with the host enzymatic system (Scheline, 1968; Nicholson et al., 2005; Sousa et al., 2008; Clayton et al., 2009; Haiser and Turnbaugh, 2012; Haiser et al., 2013). The indirect interaction is facilitated through the production of microbial or mammalian-microbial co-metabolites that compete for metabolism of xenobiotics or act as signaling molecules that influence the host gene expression. Such interactions may complement or oppose the host's enzymatic activity,

DMD #63750

culminating in wide-ranging therapeutic consequences. The following section illustrates the roles of the gut microbiota in modulating pharmacokinetic processes and the therapeutic implications. The list of affected drugs is presented in Table 1 (Sousa et al., 2008; Clayton et al., 2009; Kaddurah-Daouk et al., 2011; Haiser and Turnbaugh, 2013; Saitta et al., 2014).

Absorption

The efficacy of statins to control hypercholesterolemia and reduce the risk of cardiovascular disease exhibits great variation among individuals that can only be partly explained by genetic differences (Verschuren et al., 2011). Simvastatin is an inactive pro-drug widely prescribed for lowering cholesterol levels. Using metabonomics, Kaddurah-Daouk *et al.* performed a targeted analysis of a panel of metabolites in the cholesterol synthesis, dietary sterol absorption and bile acid formation pathways in the plasma of 100 individuals to determine metabolic phenotypes (metabotypes) predictive of variation in cholesterol lowering efficacy of statin (Kaddurah-Daouk et al., 2011). In their study, the pre-treatment concentrations of several primary and secondary bile acids were found to correlate with the on-treatment plasma simvastatin acid (active metabolite) levels. In addition, an association in the plasma levels of simvastatin acid and seven bile acids with a single nucleotide polymorphism, rs4149056, in the gene encoding SLCO1B1 was uncovered. Bile acids and statins share transporters such as organic anion transporter SLCO1B1 in the intestine and liver (Niemi et al., 2011). The authors postulated that genetic polymorphism might have limited the transport of these substrates, possibly through competition between simvastatin and bile acids for hepatic uptake by SLCO1B1 transporter. Such competition may hence influence the pharmacokinetics, efficacy and toxicity (e.g. myopathy) of simvastatin. Other drugs that are substrates to the same class of transporters may potentially be subjected to similar interaction with the bile acids. Considering the intricate role of bile acid in drug

DMD #63750

transport, the gut microbiota may potentially modulate systemic drug absorption through affecting bile acid metabolism (Macdonald et al., 1983; Dawson, 2011; Sayin et al., 2013).

Disposition

In the liver, the metabolism of xenobiotics comprises oxidative and conjugative reactions. On the other hand, it is notable that compared to the metabolic activities of the host, the reactions associated with the gut microbiota are primarily reductive reactions and hydrolytic cleavage of conjugates such as glucuronides and sulfate conjugates that have been secreted via the bile into gastrointestinal tract (Table 1) (Scheline, 1973; Goldman, 1978; Rowland, 1988). As such, the gut microbiota can generate metabolites that are otherwise not produced by the host. Nitrazepam, a benzodiazepine drug, has been reported to induce teratogenicity (Takeno and Sakai, 1991). Incubation of nitrazepam with bacterial suspensions prepared from rat cecal contents resulted in extensive reduction to 7-aminonitrazepam, that in turn yielded 7-acetylamino nitrazepam via hepatic acetylation. These metabolites were reported to cause fetal malformation. Suppression of the nitroreductase activity of the gut microbiota by antibiotics prior to administration of nitrazepam significantly decreased the urinary and fecal excretion of the two reduced metabolites from 30% to 2% and markedly reduced the incidence of teratogenicity. This underscores the roles of gut microbiota in nitrazepam-induced teratogenicity (Takeno and Sakai, 1991).

Lovastatin is a lactone pro-drug used in the treatment of hypercholesterolemia. In a recent study by Yoo *et al.*, incubation of lovastatin with human and rat fecal preparations yielded the active β -hydroxy acid metabolite that is known to inhibit 3-hydroxy-3-methylglutaryl coenzyme-A reductase (Yoo et al., 2014). This suggested the role of gut microbes in activating lovastatin for eliciting its pharmacological effects. The administration of lovastatin to antibiotic-treated rats resulted in a reduced systemic exposure to and ~60% lower fecal

DMD #63750

production of the active β -hydroxy acid metabolite (Yoo et al., 2014). The decreased bioavailability of the active metabolite due to antibiotic consumption diminishes the therapeutic efficacy of lovastatin for cholesterol control. In a wider context, the work illustrated that drug-drug interaction can occur between antibiotics and drugs that are subjected to direct microbial metabolism.

In enterohepatic recirculation, a solute entering the gastrointestinal tract is absorbed intestinally by the enterocytes; it is then taken up into the hepatocytes via the portal vein and is biliary secreted into the intestines, where it can undergo further intestinal reabsorption to be channeled back to the systemic circulation (Roberts et al., 2002). Drugs subjected to enterohepatic recirculation are often characterized by multiple C_{\max} peaks, longer apparent half-life in plasma concentration-time profile and larger apparent volume of distribution (Roberts et al., 2002). Examples of drugs subjected to enterohepatic recirculation include irinotecan (Mathijssen et al., 2001), morphine (Walsh and Levine, 1975) and indomethacin (Duggan et al., 1975). Enterohepatic recirculation is often associated with hepatic conjugation and intestinal deconjugation of parent drug. Irinotecan is a pro-drug that is administered intravenously as a first line therapy for colorectal cancers (Pommier, 2006). However, the utilization of irinotecan in chemotherapy is affected by its dose-limiting gastrointestinal toxicity characterized by severe diarrhea in patients (Rothenberg et al., 1996). Being a pro-drug, irinotecan is known to require hydrolysis by carboxylesterase in tissue and serum to generate the active metabolite, SN-38, for its pharmacologic effect (Mathijssen et al., 2001). The active SN-38 is subjected to Phase II glucuronidation by hepatic UDP-glucuronosyltransferase 1A1 to form the inactive SN-38G which is biliary secreted into the intestines (Mathijssen et al., 2001). Bacteria are reported to be the main contributor of intestinal source of β -glucuronidase enzyme for deglucuronidation (Rod and Midtvedt, 1977; Oleson and Court, 2008). Indeed, it has been discovered that the hydrolysis of SN-38G to

DMD #63750

SN-38 by microbial β -glucuronidase is responsible for the undesirable side effect of severe diarrhea (Takasuna et al., 1996; Mathijssen et al., 2001). The manipulation of the microbial β -glucuronidase activity with β -glucuronidase inhibitors and antibiotics has been shown to prevent the production of toxic SN-38 metabolites and protect the intestines of mice against injury (Takasuna et al., 1996; Wallace et al., 2010; Roberts et al., 2013). This underscores the therapeutic potential of targeted manipulation of gut microbes in minimizing the toxicity associated with irinotecan.

Phase II conjugation is a means of drug clearance, hence, the hydrolytic deconjugating activity of the gut microbiota may potentiate the pharmacological or toxicological effects of parent drugs by augmenting their systemic exposure if the aglycones are subjected to enterohepatic recirculation (Scheline, 1973; Goldman, 1978; Rowland, 1988). In a study by Clayton *et al.* (Clayton et al., 2009), the team identified that in patients administered with 1 g of acetaminophen, individuals that have high pre-dose urinary levels of p-cresol sulfate had low post-dose urinary ratio of acetaminophen sulfate to acetaminophen glucuronide. The authors attributed the reduced metabolic clearance of acetaminophen sulfate in implicated individuals to the generation of higher levels of microbially derived p-cresol that competes with acetaminophen for Phase II sulfonation in the liver (Clayton et al., 2009). Extrapolating this finding, one may hypothesize that the gut microbiota potentially affects the disposition of other drugs whereby sulfonation is an essential metabolic pathway. Additionally, the study by Clayton *et al.* illuminated an alternative mechanism of host-gut microbiota interaction mediated via microbial metabolites or co-metabolites (Clayton et al., 2009). This mode of interaction completely bypasses the need for direct contact between the drug and gut microbiota, yet enabling the gut microbiota to exert a remote influence on the fate of drug disposition by effecting host metabotypic changes that in turn modulate the host's enzymatic activities. In light of the extensive influence of the gut microbiota on the host metabotype (Li

DMD #63750

et al., 2008; Zheng et al., 2011), it is believed that the work by Clayton *et al.* sets a new direction to investigate the pervasive influence of gut microbiota on the pharmacokinetics of drugs.

From the above examples, it is clear that the gut microbiota possesses diverse metabolic capabilities that augment or reduce the metabolic status of the host and produce active, inactive or toxic metabolites, some of which are not synthesized endogenously. Collectively, the current evidences emphasize the importance of the gut microbiota in pharmaceutical research and personalized medicine.

Elucidating Host-Gut Microbiota Interactions: A Need (Not Want)

It has been reported that ~3936 molecular entities have been approved for human use by major markets worldwide including US (Huang et al., 2011). Despite the vast metabolic potential of the gut microbiota, it has been estimated that only about 40 marketed drugs have been identified as substrates to date (Sousa et al., 2008; Haiser and Turnbaugh, 2013). The relatively few examples related to microbial xenobiotic metabolism is a reflection of our limited knowledge in this field.

Many recent metagenomics studies observed large variation in the gut microbiota composition amongst individuals across different age groups and populations (Group et al., 2009; Turnbaugh et al., 2009; Yatsunenko et al., 2012). Considering the profound metabolic roles exerted by the microbes as described earlier, such variations in gut microbial composition may hold important clinical implications. Digoxin used in treating heart failure is known to possess narrow therapeutic index and requires therapeutic drug monitoring. It has been long known that digoxin can be reduced and inactivated by gut *Eggerthella lenta* into dihydrodigoxin and dihydrodigoxigenin (Saha et al., 1983; Robertson et al., 1986). 10% of the population is known to harbor these enteric bacteria that metabolize more than 40% of the

DMD #63750

orally ingested dose to inactive metabolites prior to its absorption (Li and Jia, 2013). Co-administration of antibiotics that eradicate the gut bacteria (e.g. erythromycin and tetracycline) has been reported to decrease microbial metabolism of digoxin (Lindenbaum et al., 1981). However, not all patients harboring high abundance of *Eggerthella lenta* will reduce digoxin (Saha et al., 1983). In a recent discovery by Haiser *et al.*, the authors found that the concerted influence of colonization by distinct digoxin-reducing strains of *Eggerthella lenta*, microbial interaction and host diet (arginine) determine the pharmacokinetics of digoxin (Haiser et al., 2013). Accordingly, the variation in the abundance of these specific strains of bacteria leads to inter-individual differences in the metabolism of digoxin and influence its efficacy and toxicity outcomes. This case study further emphasized the need to scrutinize the genetic and metabolic functions represented by the microbial communities to derive a more refined understanding of the role of gut microbiota in pharmacotherapy.

Definitely, more of such studies are needed to unveil the underlying mechanisms of host-gut microbiota interaction in modulating pharmacokinetics and therapeutic outcome. Such mechanistic understanding will aid the systematic characterization of drugs that are susceptible to the metabolic influence of gut microbiota and provide insights for their therapeutic management (Jia et al., 2008; Wallace et al., 2010; Haiser and Turnbaugh, 2012; Holmes et al., 2012; LoGuidice et al., 2012; Nicholson et al., 2012; Haiser and Turnbaugh, 2013; Maurice et al., 2013; Roberts et al., 2013).

Metabonomics: Mining the Metabolome to Study Host-Microbiota Interaction

Most of the established microbial influence on pharmacokinetics and therapeutic outcomes is attributed to its direct enzymatic actions on drug. Beyond this direct action, recent studies illuminated the insidious modulatory roles of the microbial or co-metabolites produced by the

DMD #63750

microbes on the host enzymatic activities. There is now an increasing awareness of the symbiotic relationship between the host and gut microbiota and their combinatorial metabolic capacities. The host metabotype is a culmination of both host systems biology and gut microbiota biology (Martin et al., 2007; Claus et al., 2008; Martin et al., 2009; Wikoff et al., 2009; Claus et al., 2011; Zheng et al., 2011; Nicholson et al., 2012; Zhao et al., 2013). Even though the gut microbiota resides in the intestines, the vena portae and lymphatic system facilitate its interaction with the host through the transportation of metabolites via the enterohepatic circulation system. As the metabotypes are reflected within the host metabolome in biological matrices (e.g. plasma, urine and feces), it renders the metabolome an important source for elucidating the interaction between the host and gut microbiota.

Previously, there is a lack of systematic scientific techniques for elucidating the complex host-gut microbiota interaction. Fortunately, this situation has greatly improved with scientific advancement in analytical sciences, molecular biology and bioinformatics that when used in combination, greatly support the endeavor of systems biology-based investigation of host-gut microbiota interaction in pharmaceutical research. Metabonomics is defined as ‘the quantitative measurement of the dynamic multiparametric metabolic response of living systems to pathophysiological stimuli or genetic modification’ (Nicholson et al., 1999). Metabonomics is an attractive platform which provides access to this wealth of information embedded within the metabolome and valuable insights into the shared responsibility between the host and gut microbiota in modulating therapeutic outcome (Nicholson et al., 1999; Lindon et al., 2003; Nicholson and Wilson, 2003; Clayton et al., 2006; Lindon et al., 2007; Han et al., 2010; Nicholson et al., 2012). The birth of metabonomics dates back to the mid-1980s (Nicholson et al., 1999). Through the use of powerful analytical instruments such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS), scientists are able to identify and quantify the small metabolites

DMD #63750

(<1500 Da) present within the metabolome (Li et al., 2008; Pasikanti et al., 2008; Wikoff et al., 2009; Yip and Chan, 2013).

The Metabonomics Workflow and its Considerations

The typical metabonomics workflow is illustrated in Fig. 1A. Fig. 1B further illustrates the various processes involved in a metabonomics study using gas chromatography time-of-flight mass spectrometry (GC/TOFMS) as an example. In brief, the workflow starts with the research question that defines the experimental design and the choice of biological matrix. As many investigations are clinically translational in nature, urine and blood samples are analyzed most frequently due to the ease of obtaining these samples (Dunn et al., 2011). The urinary and blood metabolic profiles are known to reflect variation owing to the host, drug, environment (e.g. diet, stress and lifestyle) and gut microbiota. The samples are prepared according to the type of biological matrix being analyzed and the instrument used for performing data acquisition (Beckonert et al., 2007; Dunn et al., 2011). For example, urine is known to contain high concentration of urea which will impose gas chromatographic interference. Hence, incubation with urease is performed to remove this interference during sample preparation (Pasikanti et al., 2008; Chan et al., 2011). For serum and plasma which are rich in proteins, the proteins are first precipitated by organic solvents (Bruce et al., 2009). As for tissues, they are usually homogenized before sample extraction (Want et al., 2013). For samples that will be subjected to GC/TOFMS analysis, they are typically subjected to chemical derivatization such that the derivatized analytes are sufficiently volatile and thermally stable for analysis (Kaal and Janssen, 2008).

Metabolites are downstream end products of transcription and translation and are known to regulate gene expression and function as building blocks of more complex biological molecules. Such metabolites include amino acids, organic acids, amines, sugars, nucleotides, fatty acids and steroids which span huge polarity and molecular weight ranges. Unlike DNA,

DMD #63750

RNA and proteins that are made up of chemically well-defined building blocks, the metabolites are chemically diverse and no single analytical technique is able to measure the full complement of these metabolites. In addition, the large number of metabolites within the metabolome and the wide dynamic range of their abundances further contribute to the analytical challenges. As such, various analytical techniques such as NMR spectroscopy, GC/MS and liquid chromatography-mass spectrometry (LC/MS) are often used complementarily to broaden the metabolic coverage. This complementary approach has been adopted to profile the human metabolomes in urine, blood and cerebrospinal fluid and the findings are made available in the Human Metabolome Database (HMDB) (Wishart et al., 2008; Psychogios et al., 2011; Mandal et al., 2012; Bouatra et al., 2013; Wishart et al., 2013). Metabonomics typically generates rich data in which meaningful interpretation is made possible by systematic preprocessing of the data to workable formats for further downstream analysis using statistical tools (Wishart, 2009; Chan et al., 2011; Dunn et al., 2011; Enot et al., 2011). In applying metabonomics in pharmaceutical research, one has to be mindful of the presence of interfering chromatographic peaks derived from drugs or their metabolites which can confound the statistical differentiation of the metabolic profiles of the drug treatment group from the control during chemometric multivariate data analysis. Manual exclusion of these peaks during the data preprocessing step is often tedious and erroneous. In such cases, a useful strategy that our group has adopted is to pool quality control samples solely from the drug-naïve controls prior to sample preparation and data acquisition (Yip and Chan, 2013). These pooled quality control samples can function as references whereby their metabolic features are used for the alignment of the metabolic features derived from other samples during data preprocessing (Chan et al., 2011). While this method ensures complete exclusion of all drug-related metabolic features, one needs to be mindful that selected

DMD #63750

metabolites that are highly elevated in the drug treatment group but fall below the detection limit within the control may be accidentally excluded at times.

The identities of the marker metabolites are confirmed using authentic standards and/or relevant database libraries like HMDB, National Institute of Standards and Technology (NIST) and Golm Metabolome Database (GMD). Metabonomics has been applied to identify marker metabolites implicated in gastroenterological diseases (Yoshida et al., 2012), central nervous disorders (Quinones and Kaddurah-Daouk, 2009), cancers (Chan et al., 2009; Mal et al., 2009; Pasikanti et al., 2010a; Pasikanti et al., 2010b; Mal et al., 2012) and kidney diseases (Weiss and Kim, 2012). Metabonomics has also been employed in preclinical toxicological screening and its usefulness has been comprehensively evaluated by the Consortium for Metabonomic Toxicology (COMET) which comprises scientists from the Imperial College London and several pharmaceutical companies (Lindon et al., 2003; Lindon et al., 2005; Ohta et al., 2009; Aa et al., 2011; Zgoda-Pols et al., 2011).

Metabonomics Revealed Host-Gut Microbiota Modulation of Drug Disposition

More recently, metabonomics has been used to understand the interaction between the host and gut microbiota. Through the use of different experimental designs such as antibiotic-perturbed rodents (Zheng et al., 2011; Zhao et al., 2013), germfree versus conventional rodents (Claus et al., 2008; Wikoff et al., 2009) or through gut microbiota colonization of axenic mice (Martin et al., 2007; Claus et al., 2011), metabonomic analysis of the biological matrices (e.g. urine, plasma, fecal extracts, intestines, liver and kidney) revealed extensive gut microbiota modulation of the host systemic metabolism. Table 2 illustrates a list of metabolites with differential abundance among hosts having different gut microbial community composition. It has been found that the gut microbial communities exert profound influence on the host's metabolism and partake in the metabolism of short chain fatty acids, amino acids, primary and secondary bile acids, tryptophan and carbohydrate.

DMD #63750

The alterations of such metabolites (e.g. bile acids) as a result of combinatorial activities of the host and gut microbiota suggested broad metabolic implications on drug metabolism. In a study by Toda *et al.*, the authors determined the effects of the intestinal microbiota on CYP expression by comparing the specific pathogen-free (SPF) and germfree mice (Toda *et al.*, 2009). SPF mice are free of specific infectious microorganisms and parasites but are otherwise colonized with an undefined microbiota. They observed a higher mRNA expression of a majority of CYPs in the livers of SPF mice. Using a mouse CYP3A substrate, triazolam, the authors demonstrated a higher metabolic activity of liver microsomes extracted from the SPF mice compared with germfree mice, correlating with the higher CYP3A expression in the SPF mice. Nuclear receptors like aryl hydrocarbon receptor, constitutive androstane receptor, farnesoid X receptor and pregnane X receptor which modulate the expressions of the CYPs were also highly expressed in the livers of these SPF mice as compared to germfree mice. Interestingly, cholesterol-derived metabolites such as bile acids (e.g. lithocholic acid), steroid hormones and bilirubin have been proposed to function as activators of liver nuclear receptors and the levels of these metabolites were known to be mediated by microbial metabolism (Hylemon, 1985; Li and Chiang, 2013). As such, these studies demonstrated that the gut microbiota can modulate Phase I metabolism through influencing nuclear receptor and CYP expressions (Bjorkholm *et al.*, 2009; Toda *et al.*, 2009; Claus *et al.*, 2011).

In addition, the metabolic products of the enteric bacteria are known to impose a huge burden on the Phase II metabolic processes of the host. Using metabonomics, Wikoff *et al.* revealed large effects of gut microbiota on the metabolic profiles of the mouse serum (Wikoff *et al.*, 2009). Compared to the germfree mice, conventional mice were observed to have an exclusive presence of numerous sulfated, glycine-conjugated and glucuronide adducts. For example, indoxyl sulfate was identified exclusively in the serum of conventional mice. This

DMD #63750

metabolite is formed as a result of the Phase II sulfonation of the bacterial metabolite indole, which is derived from the enzymatic conversion of tryptophan by bacterial tryptophanase (Wikoff et al., 2009). Apart from the indole derivatives, numerous metabolites apparently resulting from Phase II processing of microbial metabolites (e.g. hippuric acid, p-cresol sulfate, phenylacetyl glycine) suggested a broad, drug-like Phase II metabolic response of the host to the microbial metabolites (Wikoff et al., 2009). This metabolic burden posed by microbial metabolites is not trivial as many drugs are rendered more polar for renal and biliary clearance by hepatic Phase II metabolism. It is clear that the complex interaction between the host and gut microbiota plays a pertinent role in influencing the metabolite, which in turn underpins the variable Phase II metabolic capacities among individuals with different gut microbiota composition.

Integrative Approach to Investigate Host-Gut Microbiota Interaction

As described earlier, metabonomics enables us to capture global perturbation of microbial metabolites and co-metabolites within the host system. From the metabonomics findings, scientists can glean complementary insights on the host-gut microbiota interaction that accounts for variation in pharmacokinetics and therapeutic outcome. To elucidate the complex nature of interaction between the host and gut microbiota more completely, it is necessary to adopt an integrative approach which encompasses the study of the host, microbiota and the drug (Fig. 2). This can include pharmacogenomics studies to evaluate for genetic polymorphism and *in vitro* assays for functional characterization of drug target receptor, metabolic enzyme and transporter of the host. The ability to characterize the microbial composition and to identify the implicated gut microbes and their metabolic activities plays a major part towards expanding our understanding of their involvement in pharmacology. The integration of the host and gut microbiota biology using

DMD #63750

pharmacokinetics, pharmacology, toxicology, metabonomics, host genomics and gut microbiota metagenomics data forms a holistic strategy to elucidate the complex host-gut microbiota interaction in pharmaceutical research. The following section summarizes the techniques that support the investigation of the gut microbiota.

Culture-based and Culture-independent Techniques

Both the culture-based technique which has traditionally been used to study microbial metabolism in pharmaceutical research and the more modern culture-independent approach to study the gut microbiota are valuable techniques. The initial work on the gut microbiota since the 1970s relies on culture-based techniques (Tuohy and McCartney, 2006). Through the use of selective growth media and conditions, more than 400 to 500 bacterial species have been identified within the human gut. The majority of gut bacteria resides in the colon and it is a major site for microbial metabolism of many endogenous and exogenous compounds (Tuohy and McCartney, 2006; Sousa et al., 2008). However, the anatomical location of the human colon prevents the direct examination of the functional activities of the microbiota. As such, *in vitro* determination of drug metabolism using culture-based technique has a particular place in pharmaceutical research as it circumvents the challenge of invasive procedures, ethical drawbacks, cost and laborious nature associated with *in vivo* investigation (Sousa et al., 2008). In this regard, static batch culture is an example of an *in vitro* method that has been frequently employed for elucidating microbial metabolism of drugs (Coates et al., 1988; Sousa et al., 2008). Such cultures attempt to closely simulate the colonic environment by placing specific strains of bacteria, cecal or intestinal contents (of animals) or feces (of animal or human) into a suitable medium under careful control of factors such as anaerobic condition and pH. Drug is added to such cultures and samples are taken intermittently to quantify the amount of drug and its metabolites. It is notable that for the majority of the 40 drugs where their pharmacokinetics is associated with microbial activity, the culture-based

DMD #63750

technique has been applied to establish the role of gut microbiota in their metabolism (Sousa et al., 2008). However, some key limitations exist with the use of culture-based techniques. Inherent to the nature of bacteria cultivation technique, this method provides an incomplete view of the phylogenetic diversity of gut microbial community as some bacteria remain uncultivable (Tuohy and McCartney, 2006). To date, less than 30% of gut bacteria species have been cultured (Fraher et al., 2012). The symbiotic relationship among gut microbiota species adds to the difficulties in characterizing and reproducing appropriate growth environment for these bacteria (Miura et al., 1980; Stams, 1994; Doern, 2000). Such constraints impede culture efforts and pose challenges in creating an environment that supports the growth of all intestinal or fecal bacteria to mimic the actual colonic environment. Furthermore, culture-based techniques might be over simplistic as they do not consider other dynamic processes that occur in intact physiological conditions such as metabolic exchange and interaction between the host and gut microbial community and absorption of fermented products (Sousa et al., 2008). Hence, *in vivo* studies are conducted complementarily with *in vitro* studies to obtain deeper insights that are otherwise not obtainable from *in vitro* culture-based investigations alone. These may involve investigating microbial metabolism by comparing bile metabolites with fecal metabolites or lower gut metabolites with upper gut metabolites or comparison of drug metabolism between germfree or antibiotic-treated animals with conventional animals (Meuldermans et al., 1994; Sousa et al., 2008; Yoo et al., 2014).

Since the 1990s, the development of molecular biology gave rise to culture-independent techniques which revolutionized our knowledge of the gut microbiota (Fraher et al., 2012). The application of molecular tools has greatly improved our understanding of the microbial community by analyzing the structural diversity and functional activities of the microbes, even for those that cannot be cultured. The two key culture-independent approaches are based

DMD #63750

on the analysis of the 16S ribosomal ribonucleic acid (rRNA) genes and the whole genome of the microbes respectively (Blaut et al., 2002; Tuohy and McCartney, 2006; Brugere et al., 2009; Dave et al., 2012; Fraher et al., 2012; Kuczynski et al., 2012; Weinstock, 2012).

Present throughout the cytoplasm of a bacterial cell are 70S ribosomes that are made up of two subunits, the 30S and 50S subunits. The 30S subunit is known to contain the 16S rRNA. The 16S rRNA gene is universally present in bacteria and has highly conserved domains flanking nine hypervariable regions which possess considerable sequence diversity to be used for distinguishing bacteria (Blaut et al., 2002; Chakravorty et al., 2007). As such, the 16S rRNA gene has been considered as a phylogenetic and evolutionary marker for bacteria identification (Blaut et al., 2002). Majority of the culture-independent techniques for the analysis of the gut microbiota are based on the analysis of the 16S rRNA genes. Such techniques include quantitative polymerase chain reaction (qPCR), denaturing gradient gel electrophoresis (DGGE), temperature gradient gel electrophoresis (TGGE), terminal restriction fragment length polymorphism (T-RFLP), fluorescence *in situ* hybridization (FISH), DNA microarrays and sequencing of 16S rRNA amplicons (Blaut et al., 2002; Tuohy and McCartney, 2006; Fraher et al., 2012). Amongst these techniques, qPCR has been widely employed in gut microbiota investigation as the method is fast, sensitive, quantitative, enables phylogenetic discrimination and targeted analysis of specific bacteria of interest through primer design (Matsuki et al., 2002; Rinttilä et al., 2004; Tuohy and McCartney, 2006; Fraher et al., 2012). However, it is subjected to inherent bias of PCR-based techniques and does not allow identification of unknown bacteria (Polz and Cavanaugh, 1998; Acinas et al., 2005; Tuohy and McCartney, 2006). On the other hand, 16S rRNA gene sequencing facilitates detection of unknown bacteria and yields information on the proportion of various microbes that in turn allows inference on the composition of microbial communities (Fraher et al., 2012). The development of next-generation sequencing techniques (e.g. 454

DMD #63750

Pyrosequencing[®], Illumina[®] and SOLiD[™]) has led to significant reduction in sequencing cost and time (Kuczynski et al., 2012), rendering these techniques to be widely adopted in research. In a study to examine the long term effects of exogenous microbiota transplantation combined with and without an antibiotic pretreatment using rat model, Maichanh *et al.* combined the application of qPCR and 16S rRNA gene sequencing to determine the degree to which the gut microbiota can be experimentally manipulated (Manichanh et al., 2010). qPCR was employed to elucidate the bacterial load present in the rat fecal samples and a decrease in bacterial load was confirmed following the administration of antibiotics. Using 16S rRNA gene sequencing, Maichanh *et al.* discovered that the exogenous transplant of cecal materials from different strains of donor rats led to a change in the fecal bacterial diversity of the recipients (without antibiotic pretreatment) such that it highly resembles the donor samples and the effect persist even up to 3 months following a single inoculation. Interestingly, pretreatment with antibiotics did not facilitate the establishment of the exogenous microbiota in the recipient rats. Instead, it culminated into a greater reshaping effect, leading to a gut microbiome composition that is distant from both the donor and long-term antibiotic treatment animal. Although this result is highly counterintuitive to the authors' original hypothesis of antibiotic helping to enhance the reshaping effect of microbiota transplantation, the authors suggested that their findings should be taken into consideration during the design of future fecal microbiota transplantation studies (Manichanh et al., 2010). Integrated approach that combines 16S rRNA gene sequencing with metabonomics has also been employed in system biology-based investigation. Using the integrated approach, Lu *et al.* revealed that arsenic significantly perturbed the gut microbiome composition of C57BL/6 mice. Correlation analysis further demonstrated that the abundance of selective perturbed bacteria was highly correlated with the altered gut microbiota-related metabolites (Lu et al., 2014).

DMD #63750

The other culture-independent technique known as whole-genome shotgun sequencing involves sequencing the entire genomes of the microbes (Dave et al., 2012; Fraher et al., 2012). This method involves random fragmentation of microbial DNA, sequencing of DNA fragments and reconstruction of overlapping sequence to form a continuous sequence (Fraher et al., 2012). Through whole-genome shotgun sequencing of the microbiome, microbial genes that encode for metabolic functions can be identified. This in turn provides insights into the potential functional activities of the microbes. In other words, whole-genome shotgun sequencing provides information on both genetic diversity and functions of the gut microbiota while 16S rRNA gene sequencing provides only information on genetic diversity. However, whole-genome shotgun sequencing comes at a higher cost and is computationally more intensive. Other drawbacks include the requirement for large amount of DNA for analysis unless genome amplification is performed and many genes identified may not have known function currently.

Conclusion

Currently, there remains limited knowledge pertaining to the roles of gut microbiota in modulating therapeutic outcome. The diverse metabolic capabilities of these gut microbes and their variable composition in human gut provide the impetus to scrutinize the intricate involvement of the gut microbes in accounting for inter-individual variability. With the advancement in omics technologies (e.g. metabonomics and metagenomics), we envisage that the deliberate and systematic integration of these technologies will empower scientists to better investigate the roles of gut microbiota in pharmacokinetics and pharmacotherapy. Novel drug candidates targeting the bacteria or their enzymes may be designed to modulate efficacy or toxicity (Jia et al., 2008; Holmes et al., 2012). The mitigation of irinotecan-induced gastrointestinal toxicity using β -glucuronidase inhibitors is one example (Wallace et

DMD #63750

al., 2010). Manipulation of gut microbiota may also be effected via the administration of probiotics, prebiotics, antibiotics and fecal transplant (Jia et al., 2008; Holmes et al., 2012; Rohlke and Stollman, 2012). Considering the pervasive influence of the gut microbes on pharmacokinetics and therapeutic outcome, careful manipulation and engineering of the gut microbes may present exciting opportunities in personalized medicine.

Authorship contributions

Wrote or contributed to the writing of the manuscript: Yip and Chan

DMD #63750

References

- Aa J, Shao F, Wang G, Huang Q, Zha W, Yan B, Zheng T, Liu L, Cao B, Shi J, Li M, Zhao C, Wang X, and Wu Z (2011) Gas chromatography time-of-flight mass spectrometry based metabolomic approach to evaluating toxicity of triptolide. *Metabolomics* **7**:217-225.
- Abu Shamat MS and Beckett AH (1983) Glyceryl trinitrate: metabolism by the intestinal flora. *The Journal of pharmacy and pharmacology* **35**.
- Acinas SG, Sarma-Rupavtarm R, Klepac-Ceraj V, and Polz MF (2005) PCR-induced sequence artifacts and bias: insights from comparison of two 16S rRNA clone libraries constructed from the same sample. *Applied and environmental microbiology* **71**:8966-8969.
- Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, and Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. *Cancer research* **60**:6921-6926.
- Arteaga S, Andrade-Cetto A, and Cardenas R (2005) Larrea tridentata (Creosote bush), an abundant plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid. *Journal of ethnopharmacology* **98**:231-239.
- Basit AW and Lacey LF (2001) Colonic metabolism of ranitidine: implications for its delivery and absorption. *Int J Pharm* **227**:157-165.
- Basit AW, Newton JM, and Lacey LF (2002) Susceptibility of the H₂-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora. *Int J Pharm* **237**:23-33.
- Bates S (2010) Progress towards personalized medicine. *Drug Discovery Today* **15**:115-120.
- Beckonert O, Keun HC, Ebbels TMD, Bundy J, Holmes E, Lindon JC, and Nicholson JK (2007) Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. *Nat Protocols* **2**:2692-2703.
- Bjorkholm B, Bok CM, Lundin A, Rafter J, Hibberd ML, and Pettersson S (2009) Intestinal microbiota regulate xenobiotic metabolism in the liver. *PLoS One* **4**:e6958.
- Blaut M, Collins MD, Welling GW, Dore J, van Loo J, and de Vos W (2002) Molecular biological methods for studying the gut microbiota: the EU human gut flora project. *The British journal of nutrition* **87 Suppl 2**:S203-211.
- Bosch TM, Meijerman I, Beijnen JH, and Schellens JH (2006) Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. *Clin Pharmacokinet* **45**:253-285.
- Bouatra S, Aziat F, Mandal R, Guo AC, Wilson MR, Knox C, Bjorn Dahl TC, Krishnamurthy R, Saleem F, Liu P, Dame ZT, Poelzer J, Huynh J, Yallou FS, Psychogios N, Dong E, Bogumil R, Roehring C, and Wishart DS (2013) The Human Urine Metabolome. *PLoS ONE* **8**:e73076.
- Bruce SJ, Tavazzi I, Parisod V, Rezzi S, Kochhar S, and Guy PA (2009) Investigation of Human Blood Plasma Sample Preparation for Performing Metabolomics Using Ultrahigh Performance Liquid Chromatography/Mass Spectrometry. *Analytical Chemistry* **81**:3285-3296.
- Brugere JF, Mihajlovski A, Missaoui M, and Peyret P (2009) Tools for stools: the challenge of assessing human intestinal microbiota using molecular diagnostics. *Expert review of molecular diagnostics* **9**:353-365.
- Caldwell J and Hawksworth GM (1973) The demethylation of methamphetamine by intestinal microflora. *Journal of Pharmacy and Pharmacology* **25**:422-424.
- Carmody RN and Turnbaugh PJ (2014) Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. *The Journal of Clinical Investigation* **124**:4173-4181.
- Chakravorty S, Helb D, Burday M, Connell N, and Alland D (2007) A detailed analysis of 16S ribosomal RNA gene segments for the diagnosis of pathogenic bacteria. *Journal of Microbiological Methods* **69**:330-339.
- Chan ECY, Koh PK, Mal M, Cheah PY, Eu KW, Backshall A, Cavill R, Nicholson JK, and Keun HC (2009) Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). *Journal of Proteome Research* **8**:352-361.

DMD #63750

- Chan ECY, Pasikanti KK, and Nicholson JK (2011) Global urinary metabolic profiling procedures using gas chromatography-mass spectrometry. *Nature Protocols* **6**:1483-1499.
- Chan IS and Ginsburg GS (2011) Personalized Medicine: Progress and Promise. *Annual Review of Genomics and Human Genetics* **12**:217-244.
- Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, and Lennard-Jones JE (1983) Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. *Digestive diseases and sciences* **28**:609-615.
- Claus SP, Ellero SL, Berger B, Krause L, Bruttin A, Molina J, Paris A, Want EJ, de Waziers I, Cloarec O, Richards SE, Wang Y, Dumas ME, Ross A, Rezzi S, Kochhar S, Van Bladeren P, Lindon JC, Holmes E, and Nicholson JK (2011) Colonization-induced host-gut microbial metabolic interaction. *mBio* **2**:e00271-00210.
- Claus SP, Tsang TM, Wang Y, Cloarec O, Skordi E, Martin FP, Rezzi S, Ross A, Kochhar S, Holmes E, and Nicholson JK (2008) Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. *Mol Syst Biol* **4**:219.
- Clayton TA, Baker D, Lindon JC, Everett JR, and Nicholson JK (2009) Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. *Proceedings of the National Academy of Sciences of the United States of America* **106**:14728-14733.
- Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Net JLL, Baker D, Walley RJ, Everett JR, and Nicholson JK (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. *Nature* **440**:1073-1077.
- Coates M, Drasar B, Mallett A, Rowland I, and Rowland I (1988) Methodological considerations for the study of bacterial metabolism, in: *Role of the Gut Flora in Toxicity and Cancer*, pp 1-21, Academic Press, San Diego.
- Dave M, Higgins PD, Middha S, and Rioux KP (2012) The human gut microbiome: current knowledge, challenges, and future directions. *Translational research : the journal of laboratory and clinical medicine* **160**:246-257.
- Dawson PA (2011) Role of the intestinal bile acid transporters in bile acid and drug disposition. *Handbook of experimental pharmacology* **201**:169-203.
- Dearing MD, Foley WJ, and McLean S (2005) The influence of plant secondary metabolites on the nutritional ecology of herbivorous terrestrial vertebrates. *Annual Review of Ecology, Evolution, and Systematics* **36**:169-189.
- Delomenie C, Fouix S, Longuemaux S, Brahimi N, Bizet C, Picard B, Denamur E, and Dupret J-M (2001) Identification and Functional Characterization of Arylamine N-Acetyltransferases in Eubacteria: Evidence for Highly Selective Acetylation of 5-Aminosalicylic Acid. *J Bacteriol* **183**:3417-3427.
- Doern GV (2000) Detection of Selected Fastidious Bacteria. *Clinical Infectious Diseases* **30**:166-173.
- Duggan DE, Hooke KF, Noll RM, and Chiu Kwan K (1975) Enterohepatic circulation of indomethacin and its role in intestinal irritation. *Biochemical Pharmacology* **24**:1749-1754.
- Dull BJ, Salata K, and Goldman P (1987) Role of the intestinal flora in the acetylation of sulfasalazine metabolites. *Biochem Pharmacol* **36**:3772-3774.
- Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-Mcintyre S, Anderson N, Brown M, Knowles JD, Halsall A, Haselden JN, Nicholls AW, Wilson ID, Kell DB, and Goodacre R (2011) Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. *Nature Protocols* **6**:1060-1083.
- Elmer GW and Rimmel RP (1984) Role of the intestinal microflora in clonazepam metabolism in the rat. *Xenobiotica* **14**:829-840.
- Enot DP, Haas B, and Weinberger KM (2011) Bioinformatics for Mass Spectrometry-Based Metabolomics, in: *Bioinformatics for Omics Data : Methods and Protocols*, pp 351-375, Humana Press.
- Fraher MH, O'Toole PW, and Quigley EM (2012) Techniques used to characterize the gut microbiota: a guide for the clinician. *Nature reviews Gastroenterology & hepatology* **9**:312-322.
- Gingell R, Bridges JW, and Williams RT (1971) The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat. *Xenobiotica* **1**:143-156.

DMD #63750

- Ginsburg GS and McCarthy JJ (2001) Personalized medicine: revolutionizing drug discovery and patient care. *Trends in Biotechnology* **19**:491-496.
- Goldin BR, Peppercorn MA, and Goldman P (1973) Contributions of host and intestinal microflora in the metabolism of L-dopa by the rat. *The Journal of pharmacology and experimental therapeutics* **186**:160-166.
- Goldman P (1978) Biochemical pharmacology of the intestinal flora. *Annu Rev Pharmacol Toxicol* **18**:523-539.
- Group NHW, Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss JA, Bonazzi V, McEwen JE, Wetterstrand KA, Deal C, Baker CC, Di Francesco V, Howcroft TK, Karp RW, Lunsford RD, Wellington CR, Belachew T, Wright M, Giblin C, David H, Mills M, Salomon R, Mullins C, Akolkar B, Begg L, Davis C, Grandison L, Humble M, Khalsa J, Little AR, Peavy H, Pontzer C, Portnoy M, Sayre MH, Starke-Reed P, Zakhari S, Read J, Watson B, and Guyer M (2009) The NIH Human Microbiome Project. *Genome Res* **19**:2317-2323.
- Guengerich FP (2006) Cytochrome P450s and other enzymes in drug metabolism and toxicity. *The AAPS journal* **8**:E101-111.
- Guinane CM and Cotter PD (2013) Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. *Therapeutic advances in gastroenterology* **6**:295-308.
- Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, and Turnbaugh PJ (2013) Predicting and manipulating cardiac drug inactivation by the human gut bacterium *Escherichia coli*. *Science* **341**:295-298.
- Haiser HJ and Turnbaugh PJ (2012) Is it time for a metagenomic basis of therapeutics? *Science* **336**:1253-1255.
- Haiser HJ and Turnbaugh PJ (2013) Developing a metagenomic view of xenobiotic metabolism. *Pharmacological research : the official journal of the Italian Pharmacological Society* **69**:21-31.
- Hamburg MA and Collins FS (2010) The Path to Personalized Medicine. *New England Journal of Medicine* **363**:301-304.
- Han J, Antunes LCM, Finlay BB, and Borchers CH (2010) Metabolomics: towards understanding host-microbe interactions. *Future Microbiology* **5**:153-161.
- Hao WL and Lee YK (2004) Microflora of the gastrointestinal tract: a review. *Methods Mol Biol* **268**:491-502.
- Holmes E, Kinross J, Gibson GR, Burcelin R, Jia W, Pettersson S, and Nicholson JK (2012) Therapeutic Modulation of Microbiota-Host Metabolic Interactions. *Science Translational Medicine* **4**:137rv136.
- Holt R (1967) The bacterial degradation of chloramphenicol. *Lancet* **1**:1259-1260.
- Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, Nguyen D-T, and Austin CP (2011) The NCGC Pharmaceutical Collection: A comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. *Science translational medicine* **3**:80ps16-80ps16.
- Hylemon PB (1985) Chapter 12 Metabolism of bile acids in intestinal microflora, in: *New Comprehensive Biochemistry* (Henry D and Jan S eds), pp 331-343, Elsevier.
- Ieiri I, Takane H, Hirota T, Otsubo K, and Higuchi S (2006) Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. *Expert opinion on drug metabolism & toxicology* **2**:651-674.
- Ingelman-Sundberg M, Oscarson M, and McLellan RA (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. *Trends in Pharmacological Sciences* **20**:342-349.
- Iyanagi T (2007) Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification. *International review of cytology* **260**:35-112.
- Jia W, Li H, Zhao L, and Nicholson JK (2008) Gut microbiota: a potential new territory for drug targeting. *Nat Rev Drug Discov* **7**:123-129.
- Kaal E and Janssen HG (2008) Extending the molecular application range of gas chromatography. *Journal of Chromatography A* **1184**:43-60.

DMD #63750

- Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng Z-B, Wiest MM, Nguyen UT, Wojnoonski K, Watkins SM, Trupp M, and Krauss RM (2011) Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment. *PLoS ONE* **6**:e25482.
- Kang DW, Park JG, Ilhan ZE, Wallstrom G, Labaer J, Adams JB, and Krajmalnik-Brown R (2013) Reduced incidence of *Prevotella* and other fermenters in intestinal microflora of autistic children. *PLoS One* **8**:e68322.
- Karasov WH (1989) Nutritional bottleneck in a herbivore, the desert woodrat (*Neotoma lepida*) *Physiol Zool* **62**:1351-1382.
- Kerb R (2006) Implications of genetic polymorphisms in drug transporters for pharmacotherapy. *Cancer letters* **234**:4-33.
- Khoury MJ, Rich EC, Randhawa G, Teutsch SM, and Niederhuber J (2009) Comparative effectiveness research and genomic medicine: An evolving partnership for 21st century medicine. *Genetics in Medicine* **11**:707-711.
- Kitamura S, Sugihara K, Kuwasako M, and Tatsumi K (1997) The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. *The Journal of pharmacy and pharmacology* **49**:253-256.
- Koch RL, Beaulieu BB, Jr., and Goldman P (1980) Role of the intestinal flora in the metabolism of misonidazole. *Biochem Pharmacol* **29**:3281-3284.
- Koch RL, Chrystal EJ, Beaulieu BB, Jr., and Goldman P (1979) Acetamide--a metabolite of metronidazole formed by the intestinal flora. *Biochem Pharmacol* **28**:3611-3615.
- Kohl KD, Weiss RB, Cox J, Dale C, and Denise Dearing M (2014) Gut microbes of mammalian herbivores facilitate intake of plant toxins. *Ecology Letters* **17**:1238-1246.
- Kostic AD, Xavier RJ, and Gevers D (2014) The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead. *Gastroenterology* **146**:1489-1499.
- Kuczynski J, Lauber CL, Walters WA, Parfrey LW, Clemente JC, Gevers D, and Knight R (2012) Experimental and analytical tools for studying the human microbiome. *Nat Rev Genet* **13**:47-58.
- Kumar V, Abbas AK, Aster JC, and Robbins SL (2013) *Robbins basic pathology*. Elsevier/Saunders, Philadelphia, PA.
- Lambert JD, Zhao D, Meyers RO, Kuester RK, Timmermann BN, and Dorr RT (2002) Nordihydroguaiaretic acid: hepatotoxicity and detoxification in the mouse. *Toxicol : official journal of the International Society on Toxicology* **40**:1701-1708.
- Leckband SG, Kelsoe JR, Dunnenberger HM, George AL, Tran E, Berger R, Muller DJ, Whirl-Carrillo M, Caudle KE, and Pirmohamed M (2013) Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing. *Clin Pharmacol Ther* **94**:324-328.
- Lederberg J (2000) Infectious history. *Science* **288**:287-293.
- Li H and Jia W (2013) Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. *Clin Pharmacol Ther* **94**:574-581.
- Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H, Zhang Y, Shen J, Pang X, Wei H, Chen Y, Lu H, Zuo J, Su M, Qiu Y, Jia W, Xiao C, Smith LM, Yang S, Holmes E, Tang H, Zhao G, Nicholson JK, Li L, and Zhao L (2008) Symbiotic gut microbes modulate human metabolic phenotypes. *Proceedings of the National Academy of Sciences of the United States of America* **105**:2117-2122.
- Li T and Chiang JY (2013) Nuclear receptors in bile acid metabolism. *Drug Metab Rev* **45**:145-155.
- Lindenbaum J, Rund DG, Butler VP, Jr., Tse-Eng D, and Saha JR (1981) Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. *The New England journal of medicine* **305**:789-794.
- Lindon JC, Holmes E, and Nicholson JK (2007) Metabonomics in pharmaceutical R & D. *FEBS Journal* **274**:1140-1151.
- Lindon JC, Keun HC, Ebbels TMD, Pearce JMT, Holmes E, and Nicholson JK (2005) The Consortium for Metabonomic Toxicology (COMET): Aims, activities and achievements. *Pharmacogenomics* **6**:691-699.
- Lindon JC, Nicholson JK, Holmes E, Antti H, Bollard ME, Keun H, Beckonert O, Ebbels TM, Reilly MD, Robertson D, Stevens GJ, Luke P, Breau AP, Cantor GH, Bible RH, Niederhauser U,

DMD #63750

- Senn H, Schlotterbeck G, Sidelmann UG, Laursen SM, Tymiak A, Car BD, Lehman-McKeeman L, Colet JM, Loukaci A, and Thomas C (2003) Contemporary issues in toxicology: The role of metabonomics in toxicology and its evaluation by the COMET project. *Toxicology and Applied Pharmacology* **187**:137-146.
- LoGuidice A, Wallace BD, Bendel L, Redinbo MR, and Boelsterli UA (2012) Pharmacologic targeting of bacterial beta-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. *The Journal of pharmacology and experimental therapeutics* **341**:447-454.
- Lu K, Abo RP, Schlieper KA, Graffam ME, Levine S, Wishnok JS, Swenberg JA, Tannenbaum SR, and Fox JG (2014) Arsenic exposure perturbs the gut microbiome and its metabolic profile in mice: an integrated metagenomics and metabolomics analysis. *Environmental health perspectives* **122**:284-291.
- Lum PY, Derry MJ, and Schadt EE (2009) Integrative genomics and drug development. *Pharmacogenomics* **10**:203-212.
- Macdonald IA, Bokkenheuser VD, Winter J, McLernon AM, and Mosbach EH (1983) Degradation of steroids in the human gut. *Journal of Lipid Research* **24**:675-700.
- Mal M, Koh PK, Cheah PY, and Chan ECY (2009) Development and validation of a gas chromatography/mass spectrometry method for the metabolic profiling of human colon tissue. *Rapid Communications in Mass Spectrometry* **23**:487-494.
- Mal M, Koh PK, Cheah PY, and Chan ECY (2012) Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry. *Analytical and Bioanalytical Chemistry* **403**:483-493.
- Mancinelli L, Cronin M, and Sadee W (2000) Pharmacogenomics: the promise of personalized medicine. *AAPS pharmSci [electronic resource]* **2**.
- Mandal R, Guo AC, Chaudhary KK, Liu P, Yallou FS, Dong E, Aziat F, and Wishart DS (2012) Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update. *Genome medicine* **4**:38.
- Manichanh C, Reeder J, Gibert P, Varela E, Llopis M, Antolin M, Guigo R, Knight R, and Guarner F (2010) Reshaping the gut microbiome with bacterial transplantation and antibiotic intake. *Genome Res* **20**:1411-1419.
- Martin FP, Dumas ME, Wang Y, Legido-Quigley C, Yap IK, Tang H, Zirah S, Murphy GM, Cloarec O, Lindon JC, Sprenger N, Fay LB, Kochhar S, van Bladeren P, Holmes E, and Nicholson JK (2007) A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. *Mol Syst Biol* **3**:112.
- Martin FP, Sprenger N, Yap IK, Wang Y, Bibiloni R, Rochat F, Rezzi S, Cherbut C, Kochhar S, Lindon JC, Holmes E, and Nicholson JK (2009) Panorganismal gut microbiome-host metabolic crosstalk. *J Proteome Res* **8**:2090-2105.
- Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, and Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). *Clinical cancer research : an official journal of the American Association for Cancer Research* **7**:2182-2194.
- Matsuki T, Watanabe K, Fujimoto J, Miyamoto Y, Takada T, Matsumoto K, Oyaizu H, and Tanaka R (2002) Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces. *Applied and environmental microbiology* **68**:5445-5451.
- Matsumoto M and Benno Y (2007) The Relationship between Microbiota and Polyamine Concentration in the Human Intestine: A Pilot Study. *Microbiology and immunology* **51**:25-35.
- Maurice CF, Haiser HJ, and Turnbaugh PJ (2013) Xenobiotics shape the physiology and gene expression of the active human gut microbiome. *Cell* **152**:39-50.
- Meuldermans W, Hendrickx J, Mannens G, Lavrijssen K, Janssen C, Bracke J, Le Jeune L, Lauwers W, and Heykants J (1994) The metabolism and excretion of risperidone after oral administration in rats and dogs. *Drug Metab Dispos* **22**:129-138.
- Miura H, Horiguchi M, and Matsumoto T (1980) Nutritional Interdependence Among Rumen Bacteria, *Bacteroides amylophilus*, *Megasphaera elsdenii*, and *Ruminococcus albus*. *Applied and environmental microbiology* **40**:294-300.

DMD #63750

- Molina DK and DiMaio VJ (2012) Normal organ weights in men: part II-the brain, lungs, liver, spleen, and kidneys. *The American journal of forensic medicine and pathology* **33**:368-372.
- Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, and Huttenhower C (2012) Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. *Genome biology* **13**:R79.
- Nebert DW, Jorge-Nebert L, and Vesell ES (2003) Pharmacogenomics and "Individualized Drug Therapy": High Expectations and Disappointing Achievements. *American Journal of Pharmacogenomics* **3**:361-370.
- Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, and Pettersson S (2012) Host-gut microbiota metabolic interactions. *Science* **336**:1262-1267.
- Nicholson JK, Holmes E, and Wilson ID (2005) Gut microorganisms, mammalian metabolism and personalized health care. *Nature Reviews Microbiology* **3**:431-438.
- Nicholson JK, Lindon JC, and Holmes E (1999) 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. *Xenobiotica* **29**:1181 - 1189.
- Nicholson JK and Wilson ID (2003) Understanding 'global' systems biology: Metabonomics and the continuum of metabolism. *Nature Reviews Drug Discovery* **2**:668-676.
- Niemi M, Pasanen MK, and Neuvonen PJ (2011) Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. *Pharmacological reviews* **63**:157-181.
- Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn MV, Ryals JA, Beebe KD, and Guo L (2009) Untargeted metabolomic profiling as an evaluative tool of fenofibrate-Induced toxicology in fischer 344 male rats. *Toxicologic Pathology* **37**:521-535.
- Okuda H, Ogura K, Kato A, Takubo H, and Watabe T (1998) A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. *The Journal of pharmacology and experimental therapeutics* **287**:791-799.
- Oleson L and Court MH (2008) Effect of the beta-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferases. *The Journal of pharmacy and pharmacology* **60**:1175-1182.
- Park B, Kitteringham N, Pirmohamed M, and Tucker G (1996) Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. *British journal of clinical pharmacology* **41**:477-491.
- Park BK and Breckenridge AM (1981) Clinical implications of enzyme induction and enzyme inhibition. *Clin Pharmacokinet* **6**:1-24.
- Pasikanti KK, Esuvaranathan K, Ho PC, Mahendran R, Kamaraj R, Wu QH, Chiong E, and Chan ECY (2010a) Noninvasive urinary metabonomic diagnosis of human bladder cancer. *Journal of Proteome Research* **9**:2988-2995.
- Pasikanti KK, Ho PC, and Chan EC (2008) Gas chromatography/mass spectrometry in metabolic profiling of biological fluids. *J Chromatogr B Analyt Technol Biomed Life Sci* **871**:202-211.
- Pasikanti KK, Norasmara J, Cai S, Mahendran R, Esuvaranathan K, Ho PC, and Chan ECY (2010b) Metabolic footprinting of tumorigenic and nontumorigenic uroepithelial cells using two-dimensional gas chromatography time-of-flight mass spectrometry. *Analytical and Bioanalytical Chemistry* **398**:1285-1293.
- Peppercorn MA and Goldman P (1972) The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. *Journal of Pharmacology and Experimental Therapeutics* **181**:555-562.
- Polz MF and Cavanaugh CM (1998) Bias in template-to-product ratios in multitemplate PCR. *Applied and environmental microbiology* **64**:3724-3730.
- Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. *Nat Rev Cancer* **6**:789-802.
- Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B, Young N, Xia J, Knox C, Dong E, Huang P, Hollander Z, Pedersen TL,

DMD #63750

- Smith SR, Bamforth F, Greiner R, McManus B, Newman JW, Goodfriend T, and Wishart DS (2011) The human serum metabolome. *PLoS One* **6**:e16957.
- Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Dore J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Meta HITC, Bork P, Ehrlich SD, and Wang J (2010) A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* **464**:59-65.
- Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto J-M, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, and Wang J (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature* **490**:55-60.
- Quinones MP and Kaddurah-Daouk R (2009) Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. *Neurobiology of Disease* **35**:165-176.
- Rafii F, Sutherland JB, Hansen EB, and Cerniglia CE (1997) Reduction of Nitrazepam by *Clostridium leptum*, a Nitroreductase-Producing Bacterium Isolated from the Human Intestinal Tract. *Clinical Infectious Diseases* **25**:S121-S122.
- Rinttilä T, Kassinen A, Malinen E, Krogius L, and Palva A (2004) Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. *Journal of Applied Microbiology* **97**:1166-1177.
- Roberts AB, Wallace BD, Venkatesh MK, Mani S, and Redinbo MR (2013) Molecular insights into microbial beta-glucuronidase inhibition to abrogate CPT-11 toxicity. *Molecular pharmacology* **84**:208-217.
- Roberts MS, Magnusson BM, Burczynski FJ, and Weiss M (2002) Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. *Clin Pharmacokinet* **41**:751-790.
- Robertson LW, Chandrasekaran A, Reuning RH, Hui J, and Rawal BD (1986) Reduction of digoxin to 20R-dihydrodigoxin by cultures of *Eubacterium lentum*. *Applied and environmental microbiology* **51**:1300-1303.
- Rod TO and Midtvedt T (1977) Origin of intestinal beta-glucuronidase in germfree, monocontaminated and conventional rats. *Acta pathologica et microbiologica Scandinavica Section B, Microbiology* **85**:271-276.
- Rohlke F and Stollman N (2012) Fecal microbiota transplantation in relapsing *Clostridium difficile* infection. *Therapeutic advances in gastroenterology* **5**:403-420.
- Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA, 3rd, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, and Von Hoff DD (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **14**:1128-1135.
- Rowland IR (1988) Interactions of the gut microflora and the host in toxicology. *Toxicologic Pathology* **16**:147-153.
- Saha JR, Butler VP, Jr., Neu HC, and Lindenbaum J (1983) Digoxin-inactivating bacteria: identification in human gut flora. *Science* **220**:325-327.
- Sahota SS, Bramley PM, and Menzies IS (1982) The fermentation of lactulose by colonic bacteria. *Journal of general microbiology* **128**:319-325.
- Saitta KS, Zhang C, Lee KK, Fujimoto K, Redinbo MR, and Boelsterli UA (2014) Bacterial beta-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. *Xenobiotica* **44**:28-35.
- Savage DC (1977) Microbial ecology of the gastrointestinal tract. *Annual review of microbiology* **31**:107-133.

DMD #63750

- Sayin Sama I, Wahlström A, Felin J, Jäntti S, Marschall H-U, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, and Bäckhed F (2013) Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist. *Cell metabolism* **17**:225-235.
- Scheline RR (1968) Drug metabolism by intestinal microorganisms. *Journal of Pharmaceutical Sciences* **57**:2021-2037.
- Scheline RR (1973) Metabolism of foreign compounds by gastrointestinal microorganisms. *Pharmacological reviews* **25**:451-523.
- Shenfield GM (2004) Genetic polymorphisms, drug metabolism and drug concentrations. *The Clinical Biochemist Reviews* **25**:203-206.
- Shu YZ, Kingston DG, Van Tassell RL, and Wilkins TD (1991) Metabolism of levamisole, an anti-colon cancer drug, by human intestinal bacteria. *Xenobiotica* **21**:737-750.
- Smith GE and Griffiths LA (1974) Metabolism of n-acylated and o-alkylated drugs by the intestinal microflora during anaerobic incubation in vitro. *Xenobiotica* **4**:477-487.
- Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, and Basit AW (2008) The gastrointestinal microbiota as a site for the biotransformation of drugs. *International Journal of Pharmaceutics* **363**:1-25.
- Spatzenegger M and Jaeger W (1995) Clinical Importance of Hepatic Cytochrome P450 in Drug Metabolism. *Drug Metabolism Reviews* **27**:397-417.
- Stams AM (1994) Metabolic interactions between anaerobic bacteria in methanogenic environments. *Antonie van Leeuwenhoek* **66**:271-294.
- Strong HA, Renwick AG, George CF, Liu YF, and Hill MJ (1987) The reduction of sulphinpyrazone and sulindac by intestinal bacteria. *Xenobiotica* **17**:685-696.
- Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, Nicholson JK, and Holmes E (2011) Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. *Proceedings of the National Academy of Sciences* **108**:4523-4530.
- Sweeney TE and Morton JM (2013) The human gut microbiome: a review of the effect of obesity and surgically induced weight loss. *JAMA surgery* **148**:563-569.
- Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, and Kamataki T (1996) Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. *Cancer research* **56**:3752-3757.
- Takeno S and Sakai T (1991) Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction. *Teratology* **44**:209-214.
- Toda T, Saito N, Ikarashi N, Ito K, Yamamoto M, Ishige A, Watanabe K, and Sugiyama K (2009) Intestinal flora induces the expression of Cyp3a in the mouse liver. *Xenobiotica* **39**:323-334.
- Toivanen P, Vaahntovu J, and Eerola E (2001) Influence of major histocompatibility complex on bacterial composition of fecal flora. *Infection and immunity* **69**:2372-2377.
- Tomalik-Scharte D, Lazar A, Fuhr U, and Kirchheiner J (2007) The clinical role of genetic polymorphisms in drug-metabolizing enzymes. *Pharmacogenomics J* **8**:4-15.
- Tozaki H, Emi Y, Horisaka E, Fujita T, Yamamoto A, and Muranishi S (1997) Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat caecal contents: Implications in peptide delivery to the colon. *Journal of Pharmacy and Pharmacology* **49**:164-168.
- Tuohy KM and McCartney AL (2006) Molecular Microbial Ecology of the Human Gut, in: *Prebiotics: Development & Application*, pp 135-155, John Wiley & Sons, Ltd.
- Turnbaugh PJ, Hamady M, Yatsunencko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, and Gordon JI (2009) A core gut microbiome in obese and lean twins. *Nature* **457**:480-484.
- Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, and Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* **444**:1027-1031.
- Verschuren JJW, Trompet S, Wessels JAM, Guchelaar H-J, de Maat MPM, Simoons ML, and Jukema JW (2011) A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? *European Heart Journal* **33**:165-175.

DMD #63750

- Volp RF and Lage GL (1978) The fate of a major biliary metabolite of digitoxin in the rat intestine. *Drug Metabolism and Disposition* **6**:418-424.
- Wadworth AN and Fitton A (1991) Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. *Drugs* **41**:647-664.
- Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh L-A, Mani S, and Redinbo MR (2010) Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme. *Science* **330**:831-835.
- Walsh CT and Levine RR (1975) Studies of the enterohepatic circulation of morphine in the rat. *The Journal of pharmacology and experimental therapeutics* **195**:303-310.
- Want EJ, Masson P, Michopoulos F, Wilson ID, Theodoridis G, Plumb RS, Shockcor J, Loftus N, Holmes E, and Nicholson JK (2013) Global metabolic profiling of animal and human tissues via UPLC-MS. *Nat Protocols* **8**:17-32.
- Watanabe K, Yamashita S, Furuno K, Kawasaki H, and Gomita Y (1995) Metabolism of omeprazole by gut flora in rats. *J Pharm Sci* **84**:516-517.
- Weinstock GM (2012) Genomic approaches to studying the human microbiota. *Nature* **489**:250-256.
- Weiss RH and Kim K (2012) Metabolomics in the study of kidney diseases. *Nature Reviews Nephrology* **8**:22-33.
- Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, and Siuzdak G (2009) Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. *Proceedings of the National Academy of Sciences of the United States of America* **106**:3698-3703.
- Wilson ID and Nicholson JK (2009) The role of gut microbiota in drug response. *Current Pharmaceutical Design* **15**:1519-1523.
- Wishart DS (2009) Computational Approaches to Metabolomics, in: *Bioinformatics Methods in Clinical Research*, pp 283-313, Humana Press.
- Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, Djoumbou Y, Mandal R, Aziat F, Dong E, Bouatra S, Sinelnikov I, Arndt D, Xia J, Liu P, Yallou F, Bjorn Dahl T, Perez-Pineiro R, Eisner R, Allen F, Neveu V, Greiner R, and Scalbert A (2013) HMDB 3.0—The Human Metabolome Database in 2013. *Nucleic Acids Research* **41**:D801-D807.
- Wishart DS, Lewis MJ, Morrissey JA, Flegel MD, Jeroncic K, Xiong Y, Cheng D, Eisner R, Gautam B, Tzur D, Sawhney S, Bamforth F, Greiner R, and Li L (2008) The human cerebrospinal fluid metabolome. *J Chromatogr B Analyt Technol Biomed Life Sci* **871**:164-173.
- Woodcock J (2007) The Prospects for "Personalized Medicine" in Drug Development and Drug Therapy. *Clin Pharmacol Ther* **81**:164-169.
- Wrighton SA and Stevens JC (1992) The Human Hepatic Cytochromes P450 Involved in Drug Metabolism. *Critical Reviews in Toxicology* **22**:1-21.
- Yap IK, Li JV, Saric J, Martin FP, Davies H, Wang Y, Wilson ID, Nicholson JK, Utzinger J, Marchesi JR, and Holmes E (2008) Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse. *J Proteome Res* **7**:3718-3728.
- Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP, Heath AC, Warner B, Reeder J, Kuczynski J, Caporaso JG, Lozupone CA, Lauber C, Clemente JC, Knights D, Knight R, and Gordon JI (2012) Human gut microbiome viewed across age and geography. *Nature* **486**:222-227.
- Yip LY and Chan ECY (2013) Chapter 8 - Gas Chromatography/Mass Spectrometry-Based Metabonomics, in: *Proteomic and Metabolomic Approaches to Biomarker Discovery* (Issaq HJ and Veenstra TD eds), pp 131-144, Academic Press, Boston.
- Yoo D-H, Kim IS, Van Le TK, Jung I-H, Yoo HH, and Kim D-H (2014) Gut Microbiota-Mediated Drug Interactions between Lovastatin and Antibiotics. *Drug Metabolism and Disposition* **42**:1508-1513.
- Yoshida M, Hatano N, Nishiumi S, Irino Y, Izumi Y, Takenawa T, and Azuma T (2012) Diagnosis of gastroenterological diseases by metabolome analysis using gas chromatography-mass spectrometry. *Journal of Gastroenterology* **47**:9-20.

DMD #63750

- Zgoda-Pols JR, Chowdhury S, Wirth M, Milburn MV, Alexander DC, and Alton KB (2011) Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: Investigation of nicotinic acid receptor agonists. *Toxicology and Applied Pharmacology* **255**:48-56.
- Zhao Y, Wu J, Li JV, Zhou NY, Tang H, and Wang Y (2013) Gut microbiota composition modifies fecal metabolic profiles in mice. *J Proteome Res* **12**:2987-2999.
- Zheng X, Xie G, Zhao A, Zhao L, Yao C, Chiu NH, Zhou Z, Bao Y, Jia W, and Nicholson JK (2011) The footprints of gut microbial-mammalian co-metabolism. *J Proteome Res* **10**:5512-5522.
- Zhou SF, Di YM, Chan E, Du YM, Chow VDW, Xue CC, Lai X, Wang JC, Li CG, Tian M, and Duan W (2008) Clinical pharmacogenetics and potential application in personalized medicine. *Current Drug Metabolism* **9**:738-784.

DMD #63750

Footnote

This work was supported by Biomedical Research Council (BMRC) grant [R-148-000-144-305].

DMD #63750

Figure Legends

Fig. 1 (A) A typical metabonomics workflow and (B) flow diagram of various processes typically involved in GC/TOFMS-based metabonomics (Chan et al., 2011).

Fig. 2 Integrative approach to study host-gut microbiota interaction in pharmaceutical research.

DMD #63750

Tables

TABLE 1 Drugs whose pharmacokinetics or therapeutic outcomes are mediated by gut microbiota.

Reaction	Drug	Bacteria or its enzymes	Consequences of gut microbiota metabolism on drug pharmacokinetics and therapeutic outcomes
Reduction	Prontosil (Gingell et al., 1971)	Azoreductase enzymes	Activation of azo-bond containing pro-drug to sulfanilamide
	Neoprontosil (Gingell et al., 1971)		
	Sulfasalazine (Peppercorn and Goldman, 1972)		
	Balsalazide (Chan et al., 1983)		
	Olsalazine (Wadworth and Fitton, 1991)		
	Nitrazepam (Rafii et al., 1997)	Nitroreductase	Co-metabolism of nitrazepam produces 7-acetylamino nitrazepam responsible for teratogenic activity: Step 1: Nitroreduction of nitrazepam to 7-aminonitrazepam by gut microbiota Step 2: 7-aminonitrazepam is converted to 7-acetylamino nitrazepam in the liver
	Clonazepam (Elmer and Rimmel, 1984)	Not reported	Nearly complete reduction to 7-aminoclonazepam
	Misonidazole	Not reported	Reduction to 1-(2-aminoimidazol-1-yl)-3-

DMD #63750

Reaction	Drug	Bacteria or its enzymes	Consequences of gut microbiota metabolism on drug pharmacokinetics and therapeutic outcomes
	(Koch et al., 1980)		methoxypropan-2-ol
	Omeprazole (Watanabe et al., 1995)	Not reported	<i>In vitro</i> reduction by gut microbiota to omeprazole sulfide metabolite. However, there was no alteration of oral <i>in vivo</i> pharmacokinetics as omeprazole is fully absorbed before reaching hindgut.
	Sulfinpyrazone (Strong et al., 1987)	Not reported	Reduction to sulfinpyrazone sulfide metabolite (solely by gut microbiota)
	Sulindac (Strong et al., 1987)	Not reported	Reduction to sulindac sulfide metabolite
	Digoxin (Lindenbaum et al., 1981; Haiser et al., 2013)	<i>Eggerthella lenta</i>	Reduction to inactive metabolites (e.g. dihydrodigoxin or dihydrodigoxigenin) by gut microbiota reduce therapeutic efficacy
	Zonisamide (Kitamura et al., 1997)	<i>Clostridium sporogenes</i>	Reduction to 2-sulphamoylacetylphenol
	Metronidazole (Koch et al., 1979)	<i>Clostridium perfringens</i>	Reduction to N-(2-hydroxyethyl)-oxamic acid and acetamide
Hydrolysis	Lactulose (Sahota et al., 1982)	<i>Lactobacillus</i> , <i>Bacteroides</i> and <i>Clostridium</i>	Therapeutic activity depends on its metabolism by intestinal bacteria to form lactic and acetic acids
	Sorivudine (Okuda et al., 1998)	<i>Bacteroides</i> species (e.g. <i>Bacteroides eggerthii</i> and <i>Bacteroides</i>	A major metabolite of sorivudine, (E)-5-(2-bromovinyl)uracil, generated from microbial metabolism of the drug was found to inactivate a key hepatic enzyme

DMD #63750

Reaction	Drug	Bacteria or its enzymes	Consequences of gut microbiota metabolism on drug pharmacokinetics and therapeutic outcomes
		<i>vulgatus</i>)	involved in the metabolism of 5-fluorouracil. Co-administration of sorivudine and 5-fluorouracil resulted in drug interactions that led to death.
Deconjugation of drugs excreted in bile as inactive conjugates	Digitoxin (Volp and Lage, 1978)	β -glucuronidase	Hydrolysis of glucuronide
	Indomethacin (Saitta et al., 2014)		Hydrolysis of glucuronide of indomethacin release the aglycone which leads to gastrointestinal toxicity
	Morphine (Walsh and Levine, 1975)		Hydrolysis of glucuronide
	Irinotecan (Roberts et al., 2013)		Hydrolysis of SN-38 glucuronide of irinotecan (pro-drug) release SN-38 in the intestines which leads to gastrointestinal toxicity
Removal of succinate group	Succinylsulfathiazole (Sousa et al., 2008)	Not reported	Activation of pro-drug to sulfathiazole
Dehydroxylation	L-Dopa (Goldin et al., 1973)	Not reported	Alteration of L-dopa pharmacokinetics by gut microbiota metabolism to form m-tyramine and m-hydroxyphenylacetic acid
Acetylation	5-Aminosalicylic acid (Dull et al., 1987; Delomenie et al.,	N-acetyltransferase	Acetylation to form acetylated 5-aminosalicylic acid

DMD #63750

Reaction	Drug	Bacteria or its enzymes	Consequences of gut microbiota metabolism on drug pharmacokinetics and therapeutic outcomes
	2001)		
Deacetylation	Phenacetin (Smith and Griffiths, 1974)	Not reported	Formation of p-phenetidin from deacetylation reaction is correlated with toxicities such as methemoglobinemia and nephritis
Cleavage of N-oxide bond	Ranitidine (Basit and Lacey, 2001)	Not reported	Susceptible to N-oxide bond cleavage by gut bacteria
	Nizatidine (Basit et al., 2002)	Not reported	Susceptible to N-oxide bond cleavage by gut bacteria
Proteolysis	Insulin (Tozaki et al., 1997)	Not reported	Susceptible to proteolysis
	Calcitonin (Tozaki et al., 1997)	Not reported	Susceptible to proteolysis
Denitration	Glyceryl trinitrate (Abu Shamat and Beckett, 1983; Sousa et al., 2008)	Not reported	Generate glyceryl-1,3-dinitrate, glyceryl-1,2-dinitrate, glyceryl-1-mononitrate and glyceryl-2-mononitrate
	Isosorbide dinitrate (Sousa et al., 2008)	Not reported	Generate isomeric mononitrates and isosorbide
Amine formation and hydrolysis of amide linkage	Chloramphenicol (Holt, 1967)	Not reported	Metabolized to metabolites such as p-aminophenyl-2-amino-1,3-propanediol. Aplasia of the marrow, the most serious complication of chloramphenicol, has been proposed to be due to the activity of the intestinal microbiota.

DMD #63750

Reaction	Drug	Bacteria or its enzymes	Consequences of gut microbiota metabolism on drug pharmacokinetics and therapeutic outcomes
Thiazole ring-opening	Levamisole (Shu et al., 1991)	<i>Bacteroides</i> and <i>Clostridium</i> species	Generate levametabol-I, II and III metabolites
Isoxazole scission	Risperidone (Meuldermans et al., 1994)	Not reported	Scission of the isoxazole in the benzisoxazole ring system of risperidone is a major metabolic pathway contributed by the gut microbiota
N-demethylation	Methamphetamine (Caldwell and Hawksworth, 1973)	Not reported	Converted to amphetamine by gut microbiota. May be inconsequential to man since the parent drug is quite efficiently absorbed in the upper gastrointestinal tract.
Competition of microbial metabolite for Phase II drug clearance	Acetaminophen (Clayton et al., 2009)	Bacteria like <i>Clostridium difficile</i> is a p-cresol producer	High pre-dose levels of microbial metabolite p-cresol compete for clearance by hepatic sulfotransferase and diminish the host's metabolic capacity for Phase II sulfonation of acetaminophen.
Competition of microbial metabolite for hepatic uptake of drug	Simvastatin (Kaddurah-Daouk et al., 2011)	Bacteria like <i>Lactobacillus</i> is involved in production of coprostanol	Microbially derived secondary bile acids may compete with simvastatin for hepatic uptake by SLCO1B1 transporters, thereby affecting the pharmacokinetics and pharmacodynamics of simvastatin, and increasing the risk of myopathy.

DMD #63750

TABLE 2 List of metabolites modulated in host harboring different gut microbial community. The biological matrices in which differential abundance of these microbial-related metabolites are reported and the respective analytical platforms (NMR, LC or GC/MS) used for detection of these metabolites are provided to facilitate design and interpretation of metabonomic studies on host-gut microbiota interaction. Readers are encouraged to refer to literature such as (Nicholson et al., 2012) for the related bacteria and biological functions or consequences of the metabolites.

Metabolites	Biological matrix#	Analytical platform	Host	References
Bile acids				
Chenodeoxycholic acid	P, K, H, F (#refer to abbreviations at table footnote)	LC	Rat	(Swann et al., 2011; Zheng et al., 2011)
Cholic acid	P, L, K, H, F	NMR, LC	Mice, Rat	(Swann et al., 2011; Zheng et al., 2011; Zhao et al., 2013)
Deoxycholic acid	P, L, K, F	NMR, LC	Mice, Rat	(Swann et al., 2011; Zhao et al., 2013)
Glycochenodeoxycholate	P, K, H, L	LC	Rat	(Swann et al., 2011)
Glycocholic acid	P, K, H, L	LC	Rat	(Swann et al., 2011)
Glycodeoxycholic acid	P, K, H, L	LC	Rat	(Swann et al., 2011)
Hyochoolic acid	K, H	LC	Rat	(Swann et al., 2011)

DMD #63750

Metabolites	Biological matrix#	Analytical platform	Host	References
Hyodeoxycholic acid	K, H, L, F	LC	Rat	(Swann et al., 2011; Zheng et al., 2011)
Taurochenoxycholic acid	P, L, K, H	LC	Rat	(Swann et al., 2011)
Taurocholic acid	P, L, K, H, F	NMR, LC	Mice, Rat	(Swann et al., 2011; Zhao et al., 2013)
Taurodeoxycholic acid	P, K, H	LC	Rat	(Swann et al., 2011)
Tauro-α-muricholic acid	K	LC	Rat	(Swann et al., 2011)
Tauro-β-muricholic acid	P, L, K, H, F	NMR, LC	Mice, Rat	(Swann et al., 2011; Zhao et al., 2013)
Tauro-ω-muricholic acid	K	LC	Rat	(Swann et al., 2011)
Ursodeoxycholic acid	P, K, H, L	LC	Rat	(Swann et al., 2011)
α-Muricholic acid	L, K, H	LC	Rat	(Swann et al., 2011)
β-Muricholic acid	P, L, K	LC	Rat	(Swann et al., 2011)
ω-Muricholic acid	K, H	LC	Rat	(Swann et al., 2011)
Choline metabolites				
Betaine	K	NMR	Mice	(Claus et al., 2008)
Dimethylamine	U	NMR	Mice	(Claus et al., 2008)
Trimethylamine	U	NMR	Mice	(Claus et al., 2008)
Trimethylamine N-oxide	U, L	NMR	Mice	(Claus et al., 2008)
Phenolic, benzoyl and phenyl derivatives				
2-(4-hydroxyphenyl)propionic	F	NMR	Mice	(Zhao et al., 2013)

DMD #63750

Metabolites	Biological matrix#	Analytical platform	Host	References
acid				
3-(3,4-Dihydroxyphenyl)lactic acid	U	LC	Rat	(Zheng et al., 2011)
3-(3-Hydroxyphenyl)propanoic acid	F, U	GC	Rat	(Zheng et al., 2011)
3-Hydroxycinnamic acid	U	NMR	Mice	(Claus et al., 2008)
4-Hydroxyphenylpropionic acid	U	NMR, LC	Mice, Rat	(Claus et al., 2008; Zheng et al., 2011)
4-Hydroxyphenylpyruvic acid	U	LC	Rat	(Zheng et al., 2011)
5-Phenylvaleric acid	F	LC	Rat	(Zheng et al., 2011)
Aminophenol	F	LC	Rat	(Zheng et al., 2011)
Benzoyl glucuronide	U	LC	Rat	(Zheng et al., 2011)
Cinnamoylglycine	P	LC	Mice	(Wikoff et al., 2009)
Hippuric acid	U, P	NMR, LC, GC	Mice, Rat	(Claus et al., 2008; Yap et al., 2008; Wikoff et al., 2009; Zheng et al., 2011)
Hydroxyphenylacetyl glycine	U	LC	Rat	(Zheng et al., 2011)
Hydroxyphenyllactic acid	F	LC	Rat	(Zheng et al., 2011)
m-Hydroxyphenylacetic acid	F, U	GC	Rat	(Zheng et al., 2011)

DMD #63750

Metabolites	Biological	Analytical	Host	References
	matrix#	platform		
N-Acetyl-L-phenylalanine	U	LC	Rat	(Zheng et al., 2011)
p-Aminobenzoic acid	F	LC	Rat	(Zheng et al., 2011)
p-Cresol	U	GC	Rat	(Zheng et al., 2011)
p-Cresol sulfate	P	LC	Mice	(Wikoff et al., 2009)
Phenol	U	GC	Rat	(Zheng et al., 2011)
Phenyl sulfate	P	LC	Mice	(Wikoff et al., 2009)
Phenylacetic acid	F, U	LC	Rat	(Zheng et al., 2011)
Phenylacetylglucine	P, U	NMR, LC	Mice	(Claus et al., 2008; Wikoff et al., 2009)
Phenylalanine	F, P, L, K, D, J, I, C	NMR, LC, GC	Mice, Rat	(Claus et al., 2008; Yap et al., 2008; Wikoff et al., 2009; Zheng et al., 2011; Zhao et al., 2013)
Phenylalanyl-hydroxyproline	F, U	LC	Rat	(Zheng et al., 2011)
Phenylethanolamine	F, U	LC	Rat	(Zheng et al., 2011)
Phenylglycine	F	LC	Rat	(Zheng et al., 2011)
Phenyllactic acid	F, U	LC, GC	Rat	(Zheng et al., 2011)
Phenylpropionylglycine	P	LC	Mice	(Wikoff et al., 2009)
p-Hydrocinnamic acid	F, U	GC	Rat	(Zheng et al., 2011)
p-Hydroxybenzaldehyde	F	GC	Rat	(Zheng et al., 2011)
p-Hydroxybenzoic acid	U	GC	Rat	(Zheng et al., 2011)

DMD #63750

Metabolites	Biological matrix#	Analytical platform	Host	References
p-Hydroxyphenylacetic acid	F, U	NMR, GC	Mice, Rat	(Zheng et al., 2011; Zhao et al., 2013)
Polyamines				
Cadaverine	F, U	GC	Rat	(Zheng et al., 2011)
Putrescine	F, U	NMR, GC	Mice, Rat	(Zheng et al., 2011) (Claus et al., 2008)
Spermidine	F	LC	Human	(Matsumoto and Benno, 2007)
Spermine	F	LC	Human	(Matsumoto and Benno, 2007)
Short chain fatty acids				
Acetic acid	F, U, L, K, D, J, I, C	NMR	Mice	(Claus et al., 2008; Yap et al., 2008)
Butyric acid	F, U	LC, GC	Rat	(Zheng et al., 2011)
Hexanoic acid	F	GC	Rat	(Zheng et al., 2011)
Isobutyric acid	F, U	GC, LC	Rat	(Zheng et al., 2011)
Isovaleric acid	F, U	NMR, LC	Mice, Rat	(Claus et al., 2008; Zheng et al., 2011)
Propionic acid	F, U	NMR, GC	Mice, Rat	(Yap et al., 2008; Zheng et al., 2011)
Tryptophan, indole derivatives				
2-Indoleacetaldehyde	F, U	LC	Rat	(Zheng et al., 2011)

DMD #63750

Metabolites	Biological matrix#	Analytical platform	Host	References
2-Indolecarboxylic acid	F, U	LC	Rat	(Zheng et al., 2011)
3-Indolepropionic acid	F	LC	Rat	(Zheng et al., 2011)
3-Methyldioxyindole	F	LC	Rat	(Zheng et al., 2011)
5-Hydroxyindoleacetic acid	U	LC	Rat	(Zheng et al., 2011)
5-Hydroxyindoleacetyl glycine	U	LC	Rat	(Zheng et al., 2011)
5-Hydroxytryptophan	U	NMR	Mice	(Claus et al., 2008)
5-Hydroxytryptophol	F, U	LC	Rat	(Zheng et al., 2011)
6-Hydroxymelatonin sulfate	F, U	LC	Rat	(Zheng et al., 2011)
Hydroxykynurenine	U	LC	Rat	(Zheng et al., 2011)
Indole	U	LC	Rat	(Zheng et al., 2011)
Indole-3-propionate	P	LC	Mice	(Wikoff et al., 2009)
Indoleacetic acid	U	LC	Rat	(Zheng et al., 2011)
Indolelactic acid	U	LC	Rat	(Zheng et al., 2011)
Indoxyl	F	LC	Rat	(Zheng et al., 2011)
Indoxyl sulfate	P, U	LC, GC	Mice, Rat	(Wikoff et al., 2009; Zheng et al., 2011)
Kynurenic acid	U	GC	Rat	(Zheng et al., 2011)
N-Acetyltryptophan	P	LC	Mice	(Wikoff et al., 2009)
N-Methyltryptamine	U	LC	Rat	(Zheng et al., 2011)
Serotonin	P	LC	Mice	(Wikoff et al., 2009)
Tryptamine	F, U	LC	Rat	(Zheng et al., 2011)

DMD #63750

Metabolites	Biological	Analytical	Host	References
	matrix#	platform		
Tryptophanol	U	LC	Rat	(Zheng et al., 2011)
Vitamins				
Biotin	U	LC	Rat	(Zheng et al., 2011)
Pantothenic acid	U	LC	Rat	(Zheng et al., 2011)
Pyridoxal	F	LC	Rat	(Zheng et al., 2011)
Pyridoxine	F	LC	Rat	(Zheng et al., 2011)
Riboflavin	F	LC	Rat	(Zheng et al., 2011)
Thiamine	F	LC	Rat	(Zheng et al., 2011)

#Abbreviations: urine (U), feces (F), kidney (K), plasma (P), liver (L), heart (H), duodenum (D), jejunum (J), ileum (I) and colon (C).




Figure 1.




Figure 2.